
    
      Eligible women who consent to participate in the study are randomly allocated into one of the
      two study groups. Women who are allocated to the study group will receive vaginal
      progesterone 400 mg [ProntogestÂ® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed
      time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which
      is closer); while the other group will serve as controls. Patients will be followed up till
      delivery for the incidence in antepartum hemorrhagic episodes.
    
  